Guggenheim Capital’s Regenxbio RGNX Stock Holding History

Guggenheim Capital’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-9,343	Closed	-$212K	–	1998
2022 Q4	$212K	Buy	+9,343	New	+$211K	﹤0.01%	1788
2021 Q3	–	Sell	-5,419	Closed	-$211K	–	2215
2021 Q2	$211K	Sell	5,419 -547	-9%	-$19.6K	﹤0.01%	2124
2021 Q1	$204K	Sell	5,966 -5,610	-48%	-$239K	﹤0.01%	2087
2020 Q4	$525K	Buy	+11,576	New	+$404K	﹤0.01%	1616
2019 Q4	–	Sell	-43,125	Closed	-$1.53M	–	2151
2019 Q3	$1.53M	Buy	43,125 +1,680	+4%	+$68.1K	0.01%	1117
2019 Q2	$2.13M	Sell	41,445 -3,150	-7%	-$157K	0.02%	1032
2019 Q1	$2.56M	Buy	44,595 +2,139	+5%	+$106K	0.02%	965
2018 Q4	$1.78M	Buy	+42,456	New	+$2.49M	0.02%	1102

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Guggenheim Capital's RGNX Position: Q1 2023 in Review

Guggenheim Capital sold out of Regenxbio (RGNX) in Q1 2023, closing a stake of 9,343 shares — an estimated $212K sold.

Guggenheim Capital first reported a position in RGNX in Q4 2018 and held it in 8 quarters. The position peaked at $2.56M in Q1 2019. 174 funds tracked by Wall St. Rank hold RGNX as of Q1 2023.

Guggenheim Capital reported no remaining Regenxbio position as of Q1 2023 after selling out during the quarter.
Guggenheim Capital sold 9,343 Regenxbio shares in Q1 2023, an estimated $212K.
Guggenheim Capital first reported a position in Regenxbio in Q4 2018 and held it in 8 quarters.
Guggenheim Capital's Regenxbio position peaked at $2.56M in Q1 2019.
174 funds tracked by Wall St. Rank held Regenxbio as of Q1 2023.

Based on Guggenheim Capital's 13F filing for Q1 2023, filed 11 May 2023.